

Amendments to the Claims:

1. (Currently Amended) A child resistant blister package comprising:
 - a film having an outer edge and a surface wherein a plurality of cavities are formed therein containing at least one medicament;
 - a cover sheet which overlies said cavities and is bonded to said film; and
 - a wall structure present above the film surface and having a height measured from the film surface to the top of the wall structure and an edge located proximal to the outer edge of the film, wherein said wall structure is coextensive with the outer edge of the film such that an interior region within the film is present raised above the surface of said film which extends throughout said film so as to envelop said plurality of cavities therein;
 - wherein the distance from the outer edge of the film to the outer edge of the wall structure proximal to the outer edge of the film ranges from about 3.175 mm to about 25.4 mm and wherein the height of the wall structure ranges from about 3.175 mm to about 12.7 mm.
2. (Original) The blister package according to Claim 1, wherein said plurality of cavities are present in at least one column.
3. (Original) The blister package according to Claim 1, wherein said plurality of cavities are present in two columns.
4. (Original) The blister package according to Claim 1, wherein said plurality of cavities are present in four columns.
5. (Original) The blister package according to Claim 1, wherein said cover sheet comprises a material selected from the group consisting of cellulose, polymer, metal, and combinations thereof.

2
BEST AVAILABLE COPY

6. (Original) The blister package according to Claim 5, the cover sheet is present in the form of a metallic foil layer and wherein the metallic foil layer comprises aluminum.

7. (Original) The blister package according to Claim 6, wherein the cover sheet further comprises a second layer attached to the bottom of said metallic foil layer.

8. (Original) The blister package according to Claim 7, wherein the second layer comprises paperboard, and wherein the cover sheet is present as a laminate.

9. (Original) The blister package according to Claim 1, wherein said film comprises a material selected from the group consisting of polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

10. (Original) The blister package according to Claim 1, wherein said wall structure comprises a material selected from the group consisting of polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

11. (Original) The blister package according to Claim 1, wherein the at least one medicament is selected from the group consisting of antibiotics, antivirals, H₂-receptor antagonists, 5HT₁ agonists, 5HT₃ antagonists, COX2-inhibitors, medicaments used in treating psychiatric conditions, medicaments used in treating metabolic conditions, anticancer medicaments, medicaments used in treating neurological conditions, medicaments used in treating cardiovascular conditions, non-steroidal anti-inflammatories medicaments, medicaments used in treating Central Nervous System conditions, medicaments employed in treating Hepatitis B and C, and combinations thereof.

BEST AVAILABLE COPY

12. (Original) The blister package according to Claim 1, wherein the at least one medicament comprises an antiviral.

13. (Original) The blister package according to Claim 12, wherein the antiviral is a nucleoside reverse transcriptase inhibitor.

14. (Original) The blister package according to Claim 1, wherein the at least one medicament comprises lamivudine, zidovudine, viramune, and combinations thereof.

15. (Original) The blister package according to Claim 1, wherein a first pharmaceutical formulation comprises lamivudine and zidovudine and a second pharmaceutical formulation comprises viramune and wherein the first pharmaceutical formulation and the second pharmaceutical formulation are present in discrete blisters.

16. (Original) The blister package according to Claim 15, wherein the blisters are present in at least two columns, and wherein the first column contains blisters comprising the first pharmaceutical formulation and the second column contains blisters comprising the second pharmaceutical formulation.

17. (Original) The blister package according to Claim 1, wherein the package is present as a compliance pack.

18. (Original) The blister package according to Claim 1, wherein the package is present as a sample pack.

19. (Original) The blister package according to Claim 1, wherein the medicament is present in an oral pharmaceutical formulation.

4
BEST AVAILABLE COPY

20. (Original) The blister package according to Claim 19, wherein the oral pharmaceutical formulation is present in a unit dosage form selected from the group consisting of a tablet, a pill, a capsule, a lozenge, and combinations thereof.

21. (Amended) A child resistant blister package comprising:

a film having an outer edge and a surface wherein a plurality of cavities are formed therein containing at least one medicament, said plurality of cavities being present in at least one column;

a cover sheet which overlies said cavities and is bonded to said film, said cover sheet including at least one layer comprising a metallic foil; and

a wall structure present above the film surface and having a height measured from the film surface to the top of the wall structure and an edge located proximal to the outer edge of the film, wherein said wall structure is coextensive with the outer edge of the film such that an interior region within the film is present raised above the surface of said film which extends throughout said film so as to envelop said plurality of cavities therein;

wherein the distance from the outer edge of the film to the outer edge of the wall structure proximal to the outer edge of the film ranges from about 3.175 mm to about 25.4 mm and wherein the height of the wall structure ranges from about 3.175 mm to about 12.7 mm.

22. (Original) The blister package according to Claim 21, wherein said plurality of cavities are present in two columns.

23. (Original) The blister package according to Claim 21, wherein said plurality of cavities are present in four columns.

24. (Original) The blister package according to Claim 21, wherein said cover sheet is present as a laminate.

BEST AVAILABLE COPY

25. (Original) The blister package according to Claim 21, wherein said film comprises a material selected from the group consisting of polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

26. (Original) The blister package according to Claim 21, wherein said wall structure comprises a material selected from the group consisting of polyvinyl chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

27. (Original) The blister package according to Claim 21, wherein the at least one medicament is selected from the group consisting of antibiotics, antivirals, H₂-receptor antagonists, 5HT₁ agonists, 5HT₃ antagonists, COX2-inhibitors, medicaments used in treating psychiatric conditions, medicaments used in treating metabolic conditions, anticancer medicaments, medicaments used in treating neurological conditions, medicaments used in treating cardiovascular conditions, non-steroidal anti-inflammatories medicaments, medicaments used in treating Central Nervous System conditions, medicaments employed in treating Hepatitis B and C, and combinations thereof.

28. (Original) The blister package according to Claim 21, wherein the at least one medicament comprises an antiviral.

29. (Original) The blister package according to Claim 28, wherein the antiviral is a nucleoside reverse transcriptase inhibitor.

30. (Original) The blister package according to Claim 21, wherein the at least one medicament comprises lamivudine, zidovudine, viramune, and combinations thereof.

BEST AVAILABLE COPY

31. (Original) The blister package according to Claim 21, wherein a first pharmaceutical formulation comprises lamivudine and zidovudine and a second pharmaceutical formulation comprises viramune and wherein the first pharmaceutical formulation and the second pharmaceutical formulation are present in discrete blisters.

32. (Original) The blister package according to Claim 31, wherein the blisters are present in at least two columns, and wherein the first column contains blisters comprising the first pharmaceutical formulation and the second column contains blisters comprising the second pharmaceutical formulation.

33. (Original) The blister package according to Claim 21, wherein the package is present as a compliance pack.

34. (Original) The blister package according to Claim 21, wherein the package is present as a sample pack.

35. (Original) The blister package according to Claim 21, wherein the medicament is present in an oral pharmaceutical formulation.

36. (Original) The blister package according to Claim 35, wherein the oral pharmaceutical formulation is present in a unit dosage form selected from the group consisting of a tablet, a pill, a capsule, a lozenge, and combinations thereof.

37. (New) The blister package according to Claim 1, wherein said wall structure is unitary with said film.

38. (New) The blister package according to Claim 21, wherein said wall structure is unitary with said film.

BEST AVAILABLE COPY